false
0001117057
0001117057
2026-11-17
2026-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): November
17, 2026
| PLANET GREEN HOLDINGS CORP. |
| (Exact name of registrant as specified in its charter) |
| Nevada |
|
001-34449 |
|
87-0430320 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
130-30
31st Ave, Suite 512
Flushing, NY |
|
11354 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (347) 799-0380
| Not Applicable |
| (Former name or former address, if changed since last report) |
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
|
PLAG |
|
NYSE American |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material
Definitive Agreement.
On November 17, 2026, a subsidiary of Planet Green Holdings Corp. (“Planet Green” or the “Company”), Hubei Taihe
Biotechnology Co., Ltd. (“Taihe Bio”), entered into a technology transfer agreement (the “Transfer Agreement”)
with Harbin Aikesailun Biotechnology Co., Ltd. (“Aikesailun Bio”) to acquire a registered immune-support health food product:
Aikesailun-branded bovine colostrum, vitamin C and lactoferrin chewable tablets (the “Product”). Under the Transfer Agreement,
Taihe Bio will acquire the Product’s proprietary formulation, production process, quality standards and related technical know-how,
together with the associated health food registration certificate rights in China. Taihe Bio agreed to pay an amount of RMB1,550,000 (US$232,500)
to Aikesailun Bio in consideration for its acquisition of the Product,
In addition, Taihe Bio
is responsible for certain transfer-related costs, including notarization, sample production and testing. Aikesailun Bio will
provide technical materials and assistance with the transfer and registration process. The Transfer Agreement also contains
provisions regarding payment suspension, delays and termination.
The foregoing
description is qualified in its entirety by reference to the Transfer Agreement, which is filed as Exhibit 10.1 to this Current
Report and incorporated herein by reference.
Item 8.01 Other Events.
On November 17, 2026, the Company issued a press release announcing that it had entered into the Transfer Agreement. A copy of the press
release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
| Exhibit
No. |
|
Description |
| 10.1 |
|
Technology Transfer Agreement, dated November 17, 2026, by and between
Hubei Taihe Biotechnology Co., Ltd. and Harbin Aikesailun Biotechnology Co., Ltd. |
| 99.1 |
|
Press Release
dated November 17, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded
within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
| Dated: November 18, 2026 |
PLANET GREEN HOLDINGS CORP. |
| |
|
| |
By: |
/s/ Bin Zhou |
| |
Name: |
Bin Zhou |
| |
Title: |
Chief Executive Officer and Chairman |
Exhibit 99.1
Planet Green Holdings Acquires Registered Lactoferrin
Immunity
Chewable Tablet, Accelerating Its Entry into
Growing Immune-Health Market
Subsidiary Taihe Bio Acquires Formulation, Production
Technology and Chinese Health Food
Registration Rights for Bovine Colostrum, Vitamin C and Lactoferrin Chewable Tablets; Asset-Light
Contract
Manufacturing Model Targets a Faster, Capital-Efficient Path to Market
NEW YORK, November 17, 2026 /PRNewswire/ —
Planet Green Holdings Corp. (NYSE American: PLAG) (“Planet Green” or the “Company”), a diversified holding
company, today announced that its wholly-owned subsidiary, Hubei Taihe Biotechnology Co., Ltd. (“Taihe Bio”), has entered
into a technology transfer agreement with Harbin Aikesailun Biotechnology Co., Ltd. (“Aikesailun Bio”) to acquire a registered
immune-support health food product: Aikesailun-branded bovine colostrum, vitamin C and lactoferrin chewable tablets (the “Product”).
Under the agreement, Taihe Bio will acquire the
Product’s proprietary formulation, production process, quality standards and related technical know-how, together with the associated
health food registration certificate rights in China.
“This acquisition is a natural
extension of our lactoferrin strategy,” said Mr. Bin Zhou, Chairman and Chief Executive Officer of Planet Green. “Rather than
starting from scratch, we are securing an already-registered health food formulation that brings together three well-recognized immune-support
ingredients: lactoferrin, bovine colostrum and vitamin C. This meaningfully strengthens our immunity product pipeline and moves us closer
to delivering high-quality chewable tablet products to Chinese consumers. We believe it positions us well to capitalize on the continued
growth of China’s lactoferrin market.”
Key Highlights
| ● | Ready-made, registered product: The Product already holds a health food registration in China. Obtaining a new registration
can be a lengthy and costly process; acquiring one allows the Company to bypass much of that time and expense. |
| ● | Development complete: Laboratory-scale and pilot-scale development are finished, positioning the Product for the next phase
of commercialization. |
| ● | Asset-light model: Taihe Bio intends to use licensed contract manufacturers rather than build its own production facilities,
designed to limit capital spending and speed time to market. |
| ● | Builds on existing strategy: The acquisition extends the Company’s previously announced lactoferrin sourcing, marketing
and distribution initiative and its chewable immunity tablet program. |
| ● | Large, growing market: China held the largest country share of the global lactoferrin market in 2025, according to Grand View
Research. |
What Is Lactoferrin?
Lactoferrin is a naturally occurring protein found
in milk, with its highest concentrations in colostrum, the nutrient-rich “first milk” produced in the days after birth. It
is one of the body’s natural defense proteins and is widely used as an ingredient in premium infant formula, immune-support supplements
and sports nutrition products. Because only small amounts can be extracted from milk, lactoferrin is a high-value specialty ingredient.
The Product combines lactoferrin with two other
well-known immune-support ingredients: bovine colostrum (the first milk produced by cows after calving) and vitamin C, in an easy-to-take
chewable tablet format.
Market Opportunity
According to Market Data Forecast, the global
lactoferrin market is expected to grow from approximately US$278 million in 2026 to approximately US$519 million by 2034, representing
a compound annual growth rate of approximately 8.1%. Grand View Research reports that China held the largest country share of that market
in 2025.
Transaction and Next Steps
Under the agreement, Aikesailun Bio will hand
over technical documentation and provide process transfer support. The parties will jointly apply to China’s State Administration
for Market Regulation (SAMR) to transfer the registration certificate to Taihe Bio, which remains subject to regulatory approval. Following
the transfer, Taihe Bio intends to engage qualified contract manufacturers holding the required production licenses to bring the Product
to commercial production.
About Planet Green Holdings Corp.
Planet Green Holdings Corp. (“Planet Green”),
headquartered in Flushing, New York, is a Nevada holding company operating through its subsidiaries in China and Canada. Planet Green
operates a diversified business portfolio ranging from consumer products to online advertising. For more information, please visit the
Company’s website at www.planetgreenholdings.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “expect,”
“estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict
or indicate future events or trends or that are not statements of historical matters. Such statements are based on our management’s
current expectations and beliefs, as well as a number of assumptions concerning future events. Such forward-looking statements are subject
to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of our control, all of which
could cause actual results to differ materially from those discussed in the forward-looking statements. Accordingly, forward-looking statements
should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking
statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or
otherwise, except as may be required under applicable securities laws. Factors that could cause actual results to differ materially from
those expressed or implied in the forward-looking statements can be found in our reports filed with the U.S. Securities and Exchange Commission,
which are available free of charge on the SEC’s website at www.sec.gov.
Investor Relations Contact
Planet Green Holdings Corp.
130-30 31st Avenue, Suite 512
Flushing, NY 11354
Tel: +1 347-370-2352
www.planetgreenholdings.com